NCT00096603已完成3 期
An Open Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 450
研究概览
简要总结
This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Previous participation in Study ACD2600g
- •For women of childbearing potential, continued use of an acceptable method of contraception for the duration of the study
排除标准
- •Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to Efalizumab
研究者
相似试验
已完成
3 期
A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390gPsoriasisNCT00109252Genentech, Inc.
已完成
2 期
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD)NCT02420379Sarepta Therapeutics, Inc.33
尚未招募
3 期
Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Pediatric PatientsUreter InjuryNCT06448143Prove pharm18
招募中
1 期
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT06690476Peking University74
已完成
4 期
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow ResponseHepatitis C, ChronicNCT01033448Hoffmann-La Roche59